Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Losartan Adjuvant Therapy for TB-Positive HCC
NCT07160361Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of lenvatinib, losartan in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
lenvatiniblosartan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07160361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160361.